122 related articles for article (PubMed ID: 9744315)
21. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
22. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
[TBL] [Abstract][Full Text] [Related]
23. Stromelysin-3 expression by mammary tumor-associated fibroblasts under in vitro breast cancer cell induction.
Wang CS; Têtu B
Int J Cancer; 2002 Jun; 99(6):792-9. PubMed ID: 12115479
[TBL] [Abstract][Full Text] [Related]
24. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
25. Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.
Escot C; Zhao Y; Puech C; Rochefort H
Breast Cancer Res Treat; 1996; 38(2):217-26. PubMed ID: 8861840
[TBL] [Abstract][Full Text] [Related]
26. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
27. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
Br J Cancer; 1997; 76(3):306-11. PubMed ID: 9252196
[TBL] [Abstract][Full Text] [Related]
28. Proteases as prognostic markers in cancer.
Duffy MJ
Clin Cancer Res; 1996 Apr; 2(4):613-8. PubMed ID: 9816210
[TBL] [Abstract][Full Text] [Related]
29. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Nielsen BS; Sehested M; Timshel S; Pyke C; Danø K
Lab Invest; 1996 Jan; 74(1):168-77. PubMed ID: 8569179
[TBL] [Abstract][Full Text] [Related]
30. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.
Okada A; Tomasetto C; Lutz Y; Bellocq JP; Rio MC; Basset P
J Cell Biol; 1997 Apr; 137(1):67-77. PubMed ID: 9105037
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
32. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
34. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
35. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
36. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
37. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Duffy MJ; Duggan C; Mulcahy HE; McDermott EW; O'Higgins NJ
Clin Chem; 1998 Jun; 44(6 Pt 1):1177-83. PubMed ID: 9625040
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
39. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
40. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Nielsen BS; Sehested M; Duun S; Rank F; Timshel S; Rygaard J; Johnsen M; Danø K
Lab Invest; 2001 Nov; 81(11):1485-501. PubMed ID: 11706057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]